Recursion Pharmaceuticals, Inc.
RXRX
Updated: 23/09/2026, 15:10:14
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
No summaries found.
- Share price
- $4.05
- Market cap
- $2.12B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Najat Khan
- Employees
- 600
- IPO date
- 16/04/2021
- Beta
- 1.071
- Last dividend
- $0.00
- Day range
- $3.90 – $4.16
- 52-week range
- $2.77 – $7.18
- 1-day performance
- 2.02%
- 1-year performance
- 46.21%
- Current drawdown (1Y)
- -43.59%
- CIK
- 0001601830
- CUSIP
- 75629V104
- ISIN
- US75629V1044
- Created
- 07/12/2025, 14:05:05
- Last update
- 23/09/2026, 15:10:14
Track Recursion Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move RXRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Zacks Investment Research • STOCK • 10/06/2026, 20:50:21
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 16:42:24
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 19:30:48
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Zacks Investment Research • STOCK • 07/05/2026, 14:30:42
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 21:51:15
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research • STOCK • 06/05/2026, 10:45:40
Recursion Reports First Quarter Financial Results and Provides Business Update
GlobeNewsWire • STOCK • 06/05/2026, 08:30:00
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
Zacks Investment Research • STOCK • 01/05/2026, 20:45:22
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Seeking Alpha • STOCK • 27/04/2026, 22:16:55
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Seeking Alpha • STOCK • 17/04/2026, 03:41:47
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Zacks Investment Research • STOCK • 16/04/2026, 20:51:14
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Zacks Investment Research • STOCK • 09/04/2026, 20:50:48